ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in...
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025SAN DIEGO, Dec. 09, 2024 (GLOBE...
BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a...
With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of...
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant...
Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San...
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE...
PRESS RELEASE EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 Paris, France,...
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09,...
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in...
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema...
Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete...
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50%...
Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell...
Study represents a significant step forward in Company’s mission to serve the broadest set of physician and patient needs with...
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial...
VALENCIA, Calif. and SYDNEY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and...
Data further validates the Company’s proprietary Senza5™ technology platform to engineer enabled CAR-T cell therapies PHILADELPHIA, Dec. 09, 2024 (GLOBE NEWSWIRE)...